Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays.

ABSTRACT:

Objective

There is evidence that gag contributes to protease inhibitor susceptibility in treatment-experienced patients. Moreover, protease inhibitor resistance-associated mutations can arise in gag in the absence of protease mutations in vitro. We wished to assess the contribution of full-length Gag to protease inhibitor susceptibility in viruses unexposed to protease inhibitors, in particular from the most common HIV-1 subtypes, namely subtype A and C.

Design

We compared the drug resistance profiles of subtype A and C cognate gag-protease (from viruses not previously exposed to protease inhibitor) to protease combined with a generic subtype B gag as in routine phenotypic testing.

Methods

We amplified gag-protease sequences from plasma-derived virus or molecular clon

SUBMITTER: Gupta RK 

PROVIDER: S-EPMC2923069 | biostudies-literature | 2010 Jul

REPOSITORIES: biostudies-literature